Astral Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 15, 2025, 8:07 pm

Quick Insight

Astral Ltd, a prominent player in the Indian plastics industry specializing in pipes and fittings, currently trades at ₹1,461 with a MarketCap of ₹39,250 Cr. The company's financial metrics reveal a high P/E ratio of 81.0, reflecting investor expectations for significant future growth. Astral Ltd boasts a respectable Return on Equity (ROE) of 14.9% and Return on Capital Employed (ROCE) of 19.7%, indicating efficient use of capital. With a healthy Operating Profit Margin (OPM) of 14% and a strong Interest Coverage Ratio (ICR) of 33.00x, the company demonstrates sound financial health. Furthermore, Astral Ltd's low Cash Conversion Cycle (CCC) of 44 days signifies efficient management of working capital.

On the flip side, Astral Ltd's Price-to-Book Value (P/BV) ratio of 16.80x appears relatively high, potentially signaling an overvalued stock compared to industry peers. The company's heavy reliance on borrowings amounting to ₹233 Cr raises concerns about its debt burden and interest rate sensitivity, especially in a volatile economic environment. Moving forward, Astral Ltd could improve its outlook by diversifying its funding sources to reduce borrowing costs and enhance financial flexibility. Moreover, the company should focus on expanding its market reach and product offerings to capitalize on growing demand for infrastructure development in India's construction sector. In a competitive market landscape, Astral Ltd's strong financial performance and strategic initiatives position it well for sustainable growth in the long term.

In conclusion, while Astral Ltd demonstrates robust financial metrics and efficient capital utilization, investors should closely monitor the company's debt levels and valuation multiples. By navigating industry trends and implementing prudent financial strategies, Astral Ltd can mitigate risks and capitalize on opportunities for value creation, offering potential upside for discerning investors in the dynamic Indian market.

Competitors of Astral Ltd

All Competitor Stocks of Astral Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:25 pm

Below is a detailed analysis of the quarterly data for Astral Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,361.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,681.00 Cr. (Mar 2025) to 1,361.00 Cr., marking a decrease of 320.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,176.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,380.00 Cr. (Mar 2025) to 1,176.00 Cr., marking a decrease of 204.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 185.00 Cr.. The value appears to be declining and may need further review. It has decreased from 302.00 Cr. (Mar 2025) to 185.00 Cr., marking a decrease of 117.00 Cr..
• For OPM %, as of Jun 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 14.00%, marking a decrease of 4.00%.
• For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
• For Interest, as of Jun 2025, the value is 12.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 72.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 65.00 Cr. (Mar 2025) to 72.00 Cr., marking an increase of 7.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 110.00 Cr.. The value appears to be declining and may need further review. It has decreased from 236.00 Cr. (Mar 2025) to 110.00 Cr., marking a decrease of 126.00 Cr..
• For Tax %, as of Jun 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 28.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 79.00 Cr.. The value appears to be declining and may need further review. It has decreased from 178.00 Cr. (Mar 2025) to 79.00 Cr., marking a decrease of 99.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.02. The value appears to be declining and may need further review. It has decreased from 6.67 (Mar 2025) to 3.02, marking a decrease of 3.65.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:25 pm

Growth

Last Updated: September 4, 2025, 11:55 pm

Balance Sheet

Last Updated: August 11, 2025, 1:40 pm

Below is a detailed analysis of the balance sheet data for Astral Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 27.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 27.00 Cr..
• For Reserves, as of Mar 2025, the value is 3,590.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,161.00 Cr. (Mar 2024) to 3,590.00 Cr., marking an increase of 429.00 Cr..
• For Borrowings, as of Mar 2025, the value is 233.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 119.00 Cr. (Mar 2024) to 233.00 Cr., marking an increase of 114.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,198.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,188.00 Cr. (Mar 2024) to 1,198.00 Cr., marking an increase of 10.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 5,048.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,496.00 Cr. (Mar 2024) to 5,048.00 Cr., marking an increase of 552.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2,712.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,299.00 Cr. (Mar 2024) to 2,712.00 Cr., marking an increase of 413.00 Cr..
• For CWIP, as of Mar 2025, the value is 116.00 Cr.. The value appears to be declining and may need further review. It has decreased from 151.00 Cr. (Mar 2024) to 116.00 Cr., marking a decrease of 35.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,220.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,046.00 Cr. (Mar 2024) to 2,220.00 Cr., marking an increase of 174.00 Cr..
• For Total Assets, as of Mar 2025, the value is 5,048.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,496.00 Cr. (Mar 2024) to 5,048.00 Cr., marking an increase of 552.00 Cr..

Notably, the Reserves (3,590.00 Cr.) exceed the Borrowings (233.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Astral Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 20.33. This value is within the healthy range. It has increased from 17.00 (Mar 23) to 20.33, marking an increase of 3.33.
• For Diluted EPS (Rs.), as of Mar 24, the value is 20.33. This value is within the healthy range. It has increased from 17.00 (Mar 23) to 20.33, marking an increase of 3.33.
• For Cash EPS (Rs.), as of Mar 24, the value is 27.63. This value is within the healthy range. It has increased from 24.24 (Mar 23) to 27.63, marking an increase of 3.39.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 121.46. It has increased from 109.95 (Mar 23) to 121.46, marking an increase of 11.51.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 121.51. It has increased from 110.00 (Mar 23) to 121.51, marking an increase of 11.51.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 209.72. It has increased from 191.77 (Mar 23) to 209.72, marking an increase of 17.95.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 35.70. This value is within the healthy range. It has increased from 31.10 (Mar 23) to 35.70, marking an increase of 4.60.
• For PBIT / Share (Rs.), as of Mar 24, the value is 28.36. This value is within the healthy range. It has increased from 24.48 (Mar 23) to 28.36, marking an increase of 3.88.
• For PBT / Share (Rs.), as of Mar 24, the value is 27.27. This value is within the healthy range. It has increased from 22.93 (Mar 23) to 27.27, marking an increase of 4.34.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 20.29. This value is within the healthy range. It has increased from 17.62 (Mar 23) to 20.29, marking an increase of 2.67.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 20.30. This value is within the healthy range. It has increased from 16.97 (Mar 23) to 20.30, marking an increase of 3.33.
• For PBDIT Margin (%), as of Mar 24, the value is 17.02. This value is within the healthy range. It has increased from 16.21 (Mar 23) to 17.02, marking an increase of 0.81.
• For PBIT Margin (%), as of Mar 24, the value is 13.52. This value is within the healthy range. It has increased from 12.76 (Mar 23) to 13.52, marking an increase of 0.76.
• For PBT Margin (%), as of Mar 24, the value is 13.00. This value is within the healthy range. It has increased from 11.95 (Mar 23) to 13.00, marking an increase of 1.05.
• For Net Profit Margin (%), as of Mar 24, the value is 9.67. This value is within the healthy range. It has increased from 9.18 (Mar 23) to 9.67, marking an increase of 0.49.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 9.68. This value is within the healthy range. It has increased from 8.85 (Mar 23) to 9.68, marking an increase of 0.83.
• For Return on Networth / Equity (%), as of Mar 24, the value is 17.13. This value is within the healthy range. It has increased from 16.84 (Mar 23) to 17.13, marking an increase of 0.29.
• For Return on Capital Employeed (%), as of Mar 24, the value is 22.59. This value is within the healthy range. It has increased from 21.66 (Mar 23) to 22.59, marking an increase of 0.93.
• For Return On Assets (%), as of Mar 24, the value is 12.14. This value is within the healthy range. It has increased from 10.44 (Mar 23) to 12.14, marking an increase of 1.70.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.01.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.03. This value is within the healthy range. It has increased from 0.02 (Mar 23) to 0.03, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 1.27. It has decreased from 1.32 (Mar 23) to 1.27, marking a decrease of 0.05.
• For Current Ratio (X), as of Mar 24, the value is 1.77. This value is within the healthy range. It has increased from 1.69 (Mar 23) to 1.77, marking an increase of 0.08.
• For Quick Ratio (X), as of Mar 24, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 23) to 0.95, marking a decrease of 0.08.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.89. This value is below the healthy minimum of 4. It has decreased from 3.99 (Mar 23) to 3.89, marking a decrease of 0.10.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 18.43. This value is below the healthy minimum of 20. It has increased from 13.20 (Mar 23) to 18.43, marking an increase of 5.23.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 13.54. This value is below the healthy minimum of 20. It has increased from 9.50 (Mar 23) to 13.54, marking an increase of 4.04.
• For Earning Retention Ratio (%), as of Mar 24, the value is 81.57. This value exceeds the healthy maximum of 70. It has decreased from 86.80 (Mar 23) to 81.57, marking a decrease of 5.23.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 86.46. This value exceeds the healthy maximum of 70. It has decreased from 90.50 (Mar 23) to 86.46, marking a decrease of 4.04.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 33.00. This value is within the healthy range. It has increased from 20.91 (Mar 23) to 33.00, marking an increase of 12.09.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 19.75. This value is within the healthy range. It has increased from 12.57 (Mar 23) to 19.75, marking an increase of 7.18.
• For Enterprise Value (Cr.), as of Mar 24, the value is 53,110.31. It has increased from 35,606.86 (Mar 23) to 53,110.31, marking an increase of 17,503.45.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 9.41. This value exceeds the healthy maximum of 3. It has increased from 6.90 (Mar 23) to 9.41, marking an increase of 2.51.
• For EV / EBITDA (X), as of Mar 24, the value is 55.30. This value exceeds the healthy maximum of 15. It has increased from 42.56 (Mar 23) to 55.30, marking an increase of 12.74.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 9.49. This value exceeds the healthy maximum of 3. It has increased from 6.97 (Mar 23) to 9.49, marking an increase of 2.52.
• For Retention Ratios (%), as of Mar 24, the value is 81.56. This value exceeds the healthy maximum of 70. It has decreased from 86.79 (Mar 23) to 81.56, marking a decrease of 5.23.
• For Price / BV (X), as of Mar 24, the value is 16.80. This value exceeds the healthy maximum of 3. It has increased from 13.27 (Mar 23) to 16.80, marking an increase of 3.53.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 9.49. This value exceeds the healthy maximum of 3. It has increased from 6.97 (Mar 23) to 9.49, marking an increase of 2.52.
• For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness